Shots:
- The BT destination follows P-lll DAPA-CKD assessing Farxiga (10mg, qd) + SOC vs PBO in 4,304 patients with CKD Stages 2-4 and elevated urinary albumin excretion, with/ out T2D across 21 countries
- Results: 39% reduction in the composite measure of worsening of renal function or risk of CV or renal death; 31% reduction in death from any cause
- Farxiga (PO, qd) is an SGLT2 inhibitor indicated in adults for the treatment of insufficiently controlled T2D as both monothx. and combination therapy as an adjunct to diet and exercise to improve glycemic control, weight loss, and BP reduction
Click here to read full press release/ article | Ref: AstraZeneca | Image: DW
Related News: AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-CKD Trial for Patients With and Without Type-2 Diabetes
The post AstraZeneca’s Farxiga Receives the US FDA’s Breakthrough Therapy Designation for Chronic Kidney Disease first appeared on PharmaShots.
